Last reviewed · How we verify
saline serum
Saline serum is an isotonic sodium chloride solution that restores fluid and electrolyte balance in the body.
Saline serum is an isotonic sodium chloride solution that restores fluid and electrolyte balance in the body. Used for Fluid and electrolyte replacement in dehydration, Maintenance of vascular volume during surgery or trauma, Vehicle for intravenous medication administration.
At a glance
| Generic name | saline serum |
|---|---|
| Also known as | normal saline; NaCl 0.9% |
| Sponsor | Hédi Chaker Hospital |
| Drug class | Crystalloid fluid / Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid Management |
| Phase | FDA-approved |
Mechanism of action
Saline serum provides essential sodium and chloride ions in physiological concentrations to maintain osmotic balance and hydration status. It is used to replace lost fluids, maintain vascular volume, and support cellular function during dehydration or blood loss. The solution mimics the electrolyte composition of blood plasma to prevent osmotic complications.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Maintenance of vascular volume during surgery or trauma
- Vehicle for intravenous medication administration
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypernatremia
- Phlebitis at injection site
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Subconjunctival Humira for Boston Keratoprosthesis (PHASE1)
- Peri-procedural Hydration to Prevent Acute Kidney Injury After Pulsed Field Ablation for Atrial Fibrillation (NA)
- Corticosteroid Meniscectomy Randomized Trial (PHASE4)
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- saline serum CI brief — competitive landscape report
- saline serum updates RSS · CI watch RSS
- Hédi Chaker Hospital portfolio CI